Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
Active Not Recruiting
This is a multi-center, open-label, Phase II clinical trial evaluating pembrolizumab in combination with carboplatin/paclitaxel as a treatment in unresectable locally advanced or metastatic melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2021
Locations: Jewish General Hospital, Montreal, Quebec +1 locations
Conditions: Metastatic Malignant Melanoma
Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer
Completed
The purpose of this study is to determine the optimal dose of nab-paclitaxel to be safely administered in combination with pembrolizumab in patients with advanced inoperable non-small cell lung cancer. The study is also aimed at evaluating the efficacy of the combination therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2021
Locations: Centre hospitalier de l'université de Montréal (CHUM), Montreal, Quebec +1 locations
Conditions: Lung Cancer
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
Completed
The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/08/2021
Locations: Clearview Cancer Institute /ID# 131434, Huntsville, Alabama +139 locations
Conditions: Non-squamous Non-small Cell Lung Cancer
Drug Eluting Balloon for Prevention of Hemodialysis Access Restenosis
Completed
The purpose of this study is to evaluate the effectiveness of paclitaxel-coated balloon catheter to prevent restenosis after PTA (percutaneous transluminal angioplasty) of hemodialysis access (HA) in comparison with the uncoated PTA balloon catheter.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/18/2021
Locations: Hôpital Charles-Lemoyne, Longueuil, Quebec +2 locations
Conditions: Arteriovenous Fistulae, Arteriovenous Graft
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
Completed
This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
01/15/2021
Locations: Scottsdale Healthcare /ID# 120473, Scottsdale, Arizona +157 locations
Conditions: Triple Negative Breast Cancer
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
Terminated
The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2020
Locations: University of South Alabama/Mitchell Cancer Institute, Mobile, Alabama +248 locations
Conditions: Non-Small Cell Lung Cancer
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Completed
This is a dose escalation study that will assess the safety and efficacy of LCL161 in combination with weekly paclitaxel in adult patients with advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
12/16/2020
Locations: Dana Farber Cancer Institute SC, Boston, Massachusetts +6 locations
Conditions: Solid Tumors
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
Completed
To study the safety and efficacy of the combination of LJM716 and BYL719 against currently available treatments of physician's choice in previously treated esophageal squamous cell carcinoma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2020
Locations: University of Chicago Medical Center Dept of Onc, Chicago, Illinois +12 locations
Conditions: Esophageal Squamous Cell Carcinoma
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer
Terminated
The purpose of this study is to evaluate the dose, antitumor activity, safety and pharmacology of MEDI-575 in combination with carboplatin/paclitaxel in subjects with previously untreated, advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/01/2020
Locations: Research Site, Fountain Valley, California +28 locations
Conditions: Non-small Cell Lung Cancer
A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
Terminated
This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/23/2020
Locations: Desert Oasis Cancer Center, Casa Grande, Arizona +142 locations
Conditions: NSCLC
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Completed
The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/13/2020
Locations: Northeast Arkansas Clinical Ch /ID# 128071, Jonesboro, Arkansas +224 locations
Conditions: Squamous Non-Small Cell Lung Cancer
Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
Completed
RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2020
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +228 locations
Conditions: Bladder Cancer